Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia
Y Chen, J Zheng, Y Weng, Z Wu, X Luo, Y Qiu… - Annals of …, 2024 - Springer
This study aimed to examine the characteristics and treatment outcomes of patients with
TP53-mutant acute myeloid leukaemia (AML) and to explore potential prognostic factors …
TP53-mutant acute myeloid leukaemia (AML) and to explore potential prognostic factors …
Novel therapies upon failure of HMA plus venetoclax
O Chan, AR Walker - Hematology, 2023 - ashpublications.org
The efficacy and tolerability of the combination of hypomethylating agents with venetoclax
(HMA-VEN) in patients with newly diagnosed acute myeloid leukemia has been a practice …
(HMA-VEN) in patients with newly diagnosed acute myeloid leukemia has been a practice …
The approach of HMA plus VEN with or without BMT for all patients with AML
HJ Male, TL Lin - Hematology, 2023 - ashpublications.org
Abstract Treatment options for acute myeloid leukemia (AML) have expanded over the last 5
years. New regimens are increasing the options for patients who previously may not have …
years. New regimens are increasing the options for patients who previously may not have …
Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+ 3 regimen
A Ohmoto, S Fuji - Expert Review of Hematology, 2023 - Taylor & Francis
Introduction Cytarabine and anthracycline combination therapy (7+ 3 regimen) is the
standard care for induction chemotherapy in adult patients with acute myeloid leukemia …
standard care for induction chemotherapy in adult patients with acute myeloid leukemia …
Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients
Y Sun, G Zhu, H Zhong - European Journal of Haematology, 2024 - Wiley Online Library
Acute myeloid leukemia (AML) is distinguished by clonal growth of myeloid precursor cells,
which impairs normal hematopoiesis. Minimal residual disease (MRD) refers to the residual …
which impairs normal hematopoiesis. Minimal residual disease (MRD) refers to the residual …
[HTML][HTML] Survival, response rates, and post-transplant outcomes in patients with acute myeloid leukemia aged 60-75 treated with high intensity chemotherapy vs. lower …
K Sahasrabudhe, Y Huang, M Rebechi, P Elder… - Frontiers in …, 2022 - frontiersin.org
The United States Food and Drug Administration has approved several oral, targeted
therapies for the treatment of Acute Myeloid Leukemia (AML) in recent years. These agents …
therapies for the treatment of Acute Myeloid Leukemia (AML) in recent years. These agents …
[HTML][HTML] Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
B Zhang, Q Liu, J Li, Y Hu, X Zhao, P Huang… - Frontiers in …, 2023 - frontiersin.org
Background The efficacy of induction chemotherapy (IC) for acute myeloid leukemia (AML)
has improved significantly with the application of targeting drugs. Our previous study …
has improved significantly with the application of targeting drugs. Our previous study …
Selective eradication of venetoclax-resistant monocytic acute myeloid leukemia with iron oxide nanozymes
S Zhang, S Lou, W Bian, J Liu, R Wang, Y Wang… - Biochemical and …, 2024 - Elsevier
The clinical treatment of human acute myeloid leukemia (AML) is rapidly progressing from
chemotherapy to targeted therapies led by the BCL-2 inhibitor venetoclax (VEN). Despite its …
chemotherapy to targeted therapies led by the BCL-2 inhibitor venetoclax (VEN). Despite its …
Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony‐stimulating factor chemotherapy as a first‐line therapy for newly …
R Huang, H He, X Xu, X Lin, Y Dong, X Wang, F Jiang… - Cancer, 2024 - Wiley Online Library
Background Both venetoclax plus a hypomethylating agent (VEN/HMA) and cytarabine,
aclarubicin, and granulocyte colony‐stimulating factor (CAG) are low‐intensity regimens for …
aclarubicin, and granulocyte colony‐stimulating factor (CAG) are low‐intensity regimens for …
Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience
Y Baba, N Hida, T Sambe, M Abe… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: The combination of venetoclax (VEN) and azacitidine (AZA)(VEN+ AZA)
leads to higher complete remission rates and longer overall survival (OS) in patients with …
leads to higher complete remission rates and longer overall survival (OS) in patients with …